ESTRO 2025 - Abstract Book

S851

Clinical - Gynaecology

ESTRO 2025

higher in the hypofractionated group, it has been effectively managed with medical treatment without serious complications, resolving in a period of less than 6 weeks.

Keywords: hypofractioned radiotherapy, cervical cancer

References: 1.- Muckaden MA, Budrukkar AN, Tongaonkar HB, Dinshaw KA. Hypofractionated radiotherapy in carcinoma cervix IIIB: Tata Memorial Hospital experience. Indian J Cancer. 2002 Oct-Dec; 39(4):127-34. PMID: 12928570. 2.- Nitin Kumar1, S N Prasad2, J K Verma3, P K Singh, A prospective randomized study to compare the outcome and tolerability of Hypofractionated chemoradiotherapy versus conventional chemoradiotherapy in advance carcinoma of cervix

3286

Proffered Paper Aspects of nodal disease in patients with locally advanced cervical cancer: report from the EMBRACE-II study Max Peters 1,2 , Ludwike W.M. van Kalmthout 1 , Petra S. Kroon 1 , Max A. Schmid 3 , Stefan Ecker 3 , Laura Motisi 4 , Primoz Petric 4 , Jacob Lindegaard 5 , Kjersti Bruheim 5 , Barbara Segedin 6 , Alina Sturdza 3 , Henrike Westerveld 7 , Supriya Chopra 8 , Fleur Huang 9 , Margit Valgma 10 , Laura Velema 11 , Cornelia G. Verhoef 12 , Li Tee Tan 13 , Taran Paulsen Hellebust 14 , Remi Nout 15 , Kari Tanderup 16 , Christian Kirisits 3 , Richard Pötter 3 , Ina M. Jürgenliemk-Schulz 1 1 Department of Radiation Oncology, UMC, Utrecht, Netherlands. 2 Department of Radiation Oncology, Radiotherapiegroep, Deventer, Netherlands. 3 Department of Radiation Oncology, Medical University Vienna, General Hospital of Vienna, Comprehensive Cancer Center, Vienna, Austria. 4 Department of Radiation Oncology, University Hospital Zürich, Zürich, Switzerland. 5 Department of Oncology, Aarhus University Hospital, Aarhus, Denmark. 6 Department of Radiation Oncology, Institute of Oncology Ljubljana, Ljubljana, Slovenia. 7 Department of Radiation Oncology, Amsterdam UMC, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands. 8 Department of Radiation Oncology, Advanced Centre for Treatment Research and Education in Cancer (ACTREC), Homi Bhabha National Institute, Navi Mumbai, India. 9 Department of Oncology, Cross Cancer Institute and University of Alberta, Edmonton, Canada. 10 Department of Oncology, North Estonia Medical Centre Foundation, Tallinn, Estonia. 11 Department of Radiation Oncology, Leiden University Medical Center, Leiden, Netherlands. 12 Department of Radiation Oncology, Radboud University Medical Center, Nijmegen, Netherlands. 13 Department of Oncology, Cambridge University Hospitals NHS Trust, Cambridge, United Kingdom. 14 Department of Medical Physics, Oslo University Hospital, Oslo, Norway. 15 Department of Radiation Oncology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, Netherlands. 16 Department of Medical Physics, Aarhus University Hospital, Aarhus, Denmark Purpose/Objective: To describe aspects of lymph node metastases (LNMs) related to radiation fields in patients with locally advanced cervical cancer (LACC) included in the international multicentre EMBRACE-II study (https://www.embracestudy.dk/CT03617133). Material/Methods: LACC patients with FIGO stages 2009 I-IVA or LNMs para-aortic up to renal veins (PAO-low) were eligible for EMBRACE II. LNMs were diagnosed by pre-treatment PET, MRI, or cytology/histology. LNMs were registered per patient, anatomical location (internal/external iliac, other pelvic, common iliac, PAO-low, inguinal), and per individual node. LNM location, MRI short axis diameter, CTV and PTV volume, FDG avidity, histological confirmation, and D98% for the nodal CTV and PTV were registered. Treatment included chemo-radiation, simultaneously integrated nodal boost and MRI-guided brachytherapy. Based on number/location of LNMs and primary tumor-related factors, patients were treated using a risk adapted elective treatment volume concept (small pelvis or large pelvis +/- PAO low +/- inguinal).